Ovarian Cancer Diagnostic Market Size & Share 2024 - 2032

Ovarian Cancer Diagnostic Market Size

Ovarian Cancer Diagnostic Market size was valued at around USD 1.54 billion in 2023 and is anticipated to register a CAGR of 6.6% between 2024 and 2032. Ovarian cancer diagnostic refers to the process of identifying and determining the presence of ovarian cancer in individuals suspected of having the disease. Ovarian cancer diagnostic procedures encompass a range of tests, examinations, and imaging techniques aimed at detecting the presence of cancerous cells or tumors in the ovaries or surrounding tissues.

The increasing incidence and prevalence of ovarian cancer worldwide have heightened the demand for effective diagnostic methods. For instance, in 2024, the American Cancer Society projects that approximately 19,680 new cases of ovarian cancer will be diagnosed among women in the U.S., while roughly 12,740 women are expected to succumb to the disease.
 

Furthermore, ongoing research and development efforts in the field of oncology which is estimated to reach USD 690 billion by 2032, including ovarian cancer have led to the discovery of novel biomarkers, imaging techniques, and diagnostic technologies. This continuous innovation enhances the accuracy, sensitivity, and specificity of cancer diagnostics, enabling earlier detection of ovarian cancer and better patient outcomes.

Ovarian Cancer Diagnostic Market Trends

Advances in medical imaging, molecular biology, and genetic testing have revolutionized ovarian cancer diagnostics. High-resolution imaging modalities, such as MRI and PET-CT scans, provide detailed visualization of ovarian tumors and metastases, aiding in accurate diagnosis and staging.
 

• Furthermore, the development of molecular, immunological assays, and genetic tests allows for the identification of specific biomarkers associated with ovarian cancer, facilitating personalized treatment strategies and prognostic assessments.
   
• For instance, in November 2022, Roche announced the FDA's approval of the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, marking the first immunohistochemistry (IHC) companion diagnostic test authorized to aid in the identification of epithelial ovarian cancer (EOC) patients.
   
• Moreover, improved awareness campaigns and the implementation of screening programs have contributed to the early detection of ovarian cancer.
   
• Women are becoming more informed about the signs and symptoms of ovarian cancer, leading to earlier consultation with healthcare providers and increased uptake of screening tests.
   

Ovarian Cancer Diagnostic Market Analysis

The market by product type is categorized into instruments/analyzers and consumables. The instruments/analyzers segment garnered USD 965.7 million revenue in 2023.
 

• There has been significant progress in the development of advanced diagnostic instruments and analyzers specifically designed for the detection and diagnosis of ovarian cancer. These technological advancements have led to the creation of more accurate, sensitive, and efficient diagnostic tools, thereby propelling the market expansion.
   
• Furthermore, with growing awareness about the importance of early detection and screening for ovarian cancer, there has been a rise in the demand for diagnostic instruments and analyzers, propelling the segment progress.
   

Learn more about the key segments shaping this market

Download Free PDF

The ovarian cancer diagnostic market by diagnostic tests is categorized into imaging test, blood test, biopsy, and other diagnostic tests. The imaging test segment is further bifurcated into ultrasound, CT scan, MRI scan, PET scan, and other imaging tests. The imaging test segment garnered USD 625.4 million revenue in 2023.
 

• Imaging tests play a pivotal role in diagnosis, imaging modalities such as diagnostic ultrasound, MRI systems, or CT scans provide detailed visualization of the ovaries and surrounding structures, aiding in the detection of ovarian tumors and assessing their characteristics, size, and location.
   
• Furthermore, by providing clear images of ovarian abnormalities, imaging tests help healthcare providers accurately identify suspicious lesions or masses, facilitating early diagnosis and appropriate management of ovarian cancer.
   

Based on cancer type, the ovarian cancer diagnostic market is segmented into epithelial tumor, germ cell tumor, stromal cell tumor, and other cancer types. The epithelial tumor segment accounted for a revenue share of 90% in 2023 and is estimated to follow similar trend over the coming years.
 

• Epithelial ovarian cancer is the most common type of ovarian cancer, comprising the majority of cases diagnosed. For instance, according to the National Institutes of Health (NIH), 85% to 90% of ovarian cancers are epithelial malignancies, typically occurring in individuals aged 40 years or older. Conversely, epithelial malignancies are rare in those under 40, with most cases in women under 30 originating from germ cells.
   
• Thus, there is a higher demand for diagnostic tools and tests specifically tailored for detecting epithelial tumors. Additionally, advancements in diagnostic technologies have improved the accuracy and efficiency of detecting epithelial ovarian tumors, further stimulating the market for diagnostic solutions within this segment.
   

The ovarian cancer diagnostic market by end-use is categorized into hospitals, diagnostic laboratories, diagnostic imaging centres, cancer research institutes, and other end-users. The hospitals segment accounted for around USD 396.4 million revenue size in 2023.
 

• The segment growth is credited to hospitals' capacity to deliver effective care for high-acuity patients, including individuals grappling with conditions like ovarian cancer, necessitating specialized diagnostic and treatment provisions.
   
• Additionally, the diagnostic and imaging services offered by hospitals enable the timely assessment of patients with suspected ovarian cancer, facilitating the prompt commencement of treatment and enhancing clinical results.
   

North America ovarian cancer diagnostic market accounted for USD 624.4 million revenue in 2023 and is predicted to witness substantial market growth.
 

• North America boasts advanced healthcare infrastructure and high levels of awareness regarding the importance of early cancer detection, leading to increased screening rates for ovarian cancer.
   
• Additionally, the region benefits from robust research and development activities, fostering the development of innovative diagnostic technologies and solutions for ovarian cancer detection.
   
• Furthermore, favorable reimbursement policies and government initiatives aimed at cancer prevention and early detection further drive market growth in North America.
   

Ovarian Cancer Diagnostic Market Share

The ovarian cancer diagnostic industry is competitive in nature, with several large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel advanced products based on different technologies is among a key market strategy. Some of the leading industry players including Abbott Laboratories, Danaher Corporation, F. Hoffmann-La Roche Ltd, Qiagen N.V. among others have a notable presence in the market.
 

Ovarian Cancer Diagnostic Market Companies

Some of the eminent market participants operating in the ovarian cancer diagnostic industry include:

• Abbott Laboratories
• Agilent Technologies
• Canon Medical Systems Corporation
• Danaher Corporation
• F. Hoffmann-La Roche Ltd.
• Fujirebio Diagnostics
• GE HealthCare Technologies Inc.
• Illumina Inc.
• Myriad Genetics
• Philips Healthcare
• Positron Corporation
• Qiagen N.V.
• Quest Diagnostics
• Siemens Healthineers AG
   

Ovarian Cancer Diagnostic Industry News

• In January 2023, Agilent Technologies Inc. announced its acquisition of Avida Biomed, an emerging life sciences company specializing in advanced target enrichment workflows. These workflows offered unique capabilities tailored for clinical researchers who utilized next-generation sequencing (NGS) methods to investigate cancer. The acquisition strengthened Agilent’s esteemed SureSelect portfolio and supported its strategic goal of expanding its footprint in the fast-evolving clinical research and diagnostics domains.
   
• In August 2021, QIAGEN and OncXerna teamed up to advance the Xerna TME panel as an IVD (in-vitro diagnostic) for Navicixizumab, an ovarian cancer treatment. This diagnostic aimed to determine if patients with angiogenesis-driven ovarian cancer could benefit from Navicixizumab. The collaboration enhanced QIAGEN’s NGS companion diagnostics in immuno-oncology, strengthening the company's competitive edge.
   

Ovarian cancer diagnostic market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:

Click here to Buy Section of this Report

 

Market, By Product Type

• Instruments/analyzers
• Consumables

Market, By Diagnostic Tests

• Imaging test
  • Ultrasound
  • CT scan
  • MRI scan
  • PET scan
  • Other imaging tests
• Blood test
  • CA125 (Cancer antigen 125)
  • HER2 (Human epidermal growth factor receptor 2)
  • BRCA (Breast cancer gene)
  • CEA (Carcinoembryonic antigen)
  • ER & PR (Estrogen receptor and progesterone receptor)
  • KRAS mutation
  • Other blood tests
• Biopsy
• Other diagnostic tests

Market, By Cancer Type

• Epithelial tumor
• Germ cell tumor
• Stromal cell tumor
• Other cancer types

Market, By End-use

• Hospitals
• Diagnostic laboratories
• Diagnostic imaging centers
• Cancer research institutes
• Other end-users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa